Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening (ICRG0101)
Breast Cancer Female, BRCA1 Mutation, BRCA2 Mutation
About this trial
This is an interventional other trial for Breast Cancer Female focused on measuring Breast cancer, broadband spectroscopy laser, liquid biospsies, cancer screening
Eligibility Criteria
Inclusion Criteria:
*For all participants :
- Adult woman capable of giving informed consent to research participation
Affiliation to the French social security system
>For Control cohort:
Woman participating in organised screening or benefiting from individual follow-up, eligible as such for a mammogram
>For Patient cohort:
woman with invasive breast cancer T0N1, T1N0-1, T2N0-1 (histologically proven) at inclusion and before any cancer treatment
>For Exploratory cohort:
- woman carrying the BRCA1/2 mutation, followed according to standard recommendations or
- woman carrying the BRCA1/2 mutation suffering from in situ BC discovered on biopsy and histologically confirmed
Exclusion Criteria:
For all participants :
- Refusal to participate
- Reluctant or unable to comply with study requirements
- Pregnant or breastfeeding woman
- History of breast cancer
For Patient cohort
- Patients with Stage III/IV or Bilateral Breast Cancer
For Control cohort:
- Invasive breast cancer suspected at mammography before liquid biopsy*
- Mammography classified ACR3 or ACR4
For Exploratory cohort:
Concomitant breast cancer
- At inclusion visit, woman for whom an invasive breast cancer will be suspected at mammography will be include in Patient cohort after an histological proof of cancer
Sites / Locations
- Hôpital La Pitié SalpêtrièreRecruiting
- Hôpital Saint-Louis
- Hôpital TenonRecruiting
- Centre Jean PERRINRecruiting
- La Chataigneraie (Selimed 63)Recruiting
- Pôle Santé RépubliqueRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Other
Other
Other
Control cohort
Patient cohort
Exploratory cohort
In this cohort, women recruited participated to organised breast cancer screening. They must not have an invasive breast cancer. They will have 3 liquid biopsy : the first at inclusion and then at each mammogram every two years (organised breast cancer screening).
In this cohort, women for who an invasive breast cancer has been diagnose will be included. Only one liquid biopsy will be collected before any treatment.
In this cohort, women with high risk of BRCA1/2 mutation but without invasive breast cancer. 6 liquid biopsies will be collected : each year after inclusion during 5 years.